BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, November 16, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegener
How this was made
The 30-second read
Why it matters
Traders can use the updated quarterly cash, operating expense run-rate, and net loss to reassess funding needs and the probability of progressing to Phase 3b initiation, while the executive-chair appointment and FDA-related commentary may influence perceived regulatory execution quality.
Market read
This is a primary quarterly disclosure plus program-readiness update, useful for reassessing liquidity and near-term trial execution risk for an OTC biotech.
What to watch
Cash is still very low (about $0.35M cash and restricted cash at Sept. 30, 2026) and liabilities are sizable versus assets, increasing sensitivity to any future dilutive financing or delays in trial initiation.
Background
BrainStorm Cell Therapeutics (OTCQB: BCLI) furnished an SEC Form 8-K with Q3 2026 results and a corporate update focused on NurOwn in ALS, including Phase 3b ENDURANCE preparations under an FDA Special Protocol Assessment.
Ticker impact
BrainStorm reports Q3 2026 financials and says it is preparing to initiate the Phase 3b ENDURANCE study of NurOwn under an FDA-agreed SPA.
Likely modest sentiment support from Phase 3b readiness updates, offset by continued small cash balance and ongoing net losses.
This is a primary 8-K with new quarter results and specific program readiness statements, but it does not include trial outcomes, financing terms, or a clear catalyst date that would drive a large repricing.
Market effects
Adds incremental signal on FDA rare-disease regulatory posture and how stem-cell neurodegeneration programs are progressing toward late-stage studies.
No clear regional spillover beyond OTC biotech sentiment.
Limited; the update is company-specific with only general reference to FDA’s rare disease framework initiative.
Counterpoint
The Phase 3b readiness language may not translate into near-term enrollment or cash runway, so the market may focus more on burn rate and liquidity risk than on regulatory progress.
Key entities
- companyBrainStorm Cell Therapeutics Inc.
OTCQB-listed adult stem cell therapeutics developer reporting Q3 2026 results and NurOwn Phase 3b ENDURANCE readiness updates.
- programNurOwn
Autologous MSC-NTF cell therapy platform for ALS; company highlights Phase 3b ENDURANCE preparations under an FDA-agreed SPA.
- regulatoryFDA Special Protocol Assessment (SPA)
FDA-agreed protocol framework referenced as supporting the planned Phase 3b ENDURANCE study.
- executiveProfessor Peter J. Pitts
Appointed Executive Chairman and Chief Strategic Regulatory and Policy Officer to lead regulatory, operational, partnership, and capital-markets initiatives.
